Journal
BMB REPORTS
Volume 56, Issue 5, Pages 275-286Publisher
KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
DOI: 10.5483/BMBRep.2023-0024
Keywords
Cancer immunotherapy; Cold tumor; Ferroptosis; Hot tumor; Immunogenic cell death; Necroptosis; Pyroptosis
Categories
Ask authors/readers for more resources
Cancer immunotherapy has shown significant therapeutic effects on certain types of cancer, but has low response rates in most solid tumors. Combination therapies that enhance tumor immunogenicity, such as immunogenic cell death and T-cell therapies, are being considered as relevant therapeutic options.
Cancer immunotherapy has been acknowledged as a new paradigm for cancer treatment, with notable therapeutic effects on certain cancer types. Despite their significant potential, clinical studies over the past decade have revealed that cancer immunotherapy has low response rates in the majority of solid tumors. One of the key causes for poor responses is known to be the relatively low immunogenicity of solid tumors. Because most solid tumors are immune desert 'cold tumors' with antitumor immunity blocked from the onset of innate immunity, combination therapies that combine validated T-based therapies with approaches that can increase tumor-immunogenicity are being considered as relevant therapeutic options. This review paper focuses on immunogenic cell death (ICD) as a way of enhancing immunogenicity in tumor tissues. We will thoroughly review how ICDs such as necroptosis, pyroptosis, and ferroptosis can improve anti-tumor immunity and outline clinical trials targeting ICD. Finally, we will discuss the potential of ICD inducers as an adjuvant for cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available